TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29024419

Group type: EXPERIMENTAL
Intervention: EpiFix and multilayer compression therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard wound care and multilayer compression therapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: EpiFix
Number of subjects: 109
Study: 27588078

Group type: EXPERIMENTAL
Intervention: Conventional treatment + oral administration of Jiawei Di Tan Tang
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 60
Study: 24827405

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 64
Study: 22568808

Group type: EXPERIMENTAL
Intervention: Roledumab (30-3000 μg i.v. and 300 μg i.m.)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Roledumab (30-3000 μg i.v.)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Roledumab (300 μg i.m.)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Roledumab
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 21755798

Group type: EXPERIMENTAL
Intervention: Scotchbond MP Plus (light-cured)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scotchbond MP Plus (chemically-cured)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Allbond 2 (light-cured)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Allbond 2 (chemically-cured)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (light-cured)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (chemically-cured)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Light-cured samples (group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chemically-cured samples (group)
Number of subjects: 60
Study: 18578856

Group type: EXPERIMENTAL
Intervention: Follow-up by the district GP
Number of subjects: 170

Group type: COMPARATOR
Intervention: Follow-up at the surgical outpatient clinic
Number of subjects: 170
Study: 15904528

Group type: EXPERIMENTAL
Intervention: Self-care educational program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 11932063

Group type: EXPERIMENTAL
Intervention: PCA morphine 1 mg/cc plus naloxone 6 microg/cc
Number of subjects: 166

Group type: COMPARATOR
Intervention: PCA morphine 1 mg/cc plus normal saline
Number of subjects: 166
Study: 9729942

Group type: EXPERIMENTAL
Intervention: Collagen-alginate dressing
Number of subjects: 75

Group type: COMPARATOR
Intervention: Gauze dressing (control)
Number of subjects: 75
Study: 8154643

Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g every 8 h)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Piperacillin (12 to 18 g/d in 4 to 6 divided doses) plus Tobramycin (1.7 to 2.0 mg/kg body weight every 8 h)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Piperacillin plus Tobramycin
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 696
Study: 2830091

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg twice a day
Number of subjects: 12
Study: 31832821

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m2 on days 1 and 8 every 21 days)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m2 on days 1, 8, and 15 every 21 days)
Number of subjects: 110
Study: 30082420

Group type: EXPERIMENTAL
Intervention: Perceived threat manipulation in a controlled laboratory setting (Experiment I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural variation of perceived threat in firefighters on duty (Experiment II)
Number of subjects: 0
Study: 27385739

Group type: EXPERIMENTAL
Intervention: High elaboration (thoughtful consideration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low elaboration (nonthoughtful consideration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second message (opposed to the first)
Number of subjects: 0
Study: 24568949

Group type: EXPERIMENTAL
Intervention: True auriculopressure (TAP)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo auriculopressure (PAP)
Number of subjects: 265
Study: 22572202

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0-3.0)
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: Apixaban vs Warfarin
Number of subjects: 18201
Study: 20934155

Group type: EXPERIMENTAL
Intervention: Intermittent administration of tisokinase (960,000 IU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous irrigation using pH-adjusted lactate Ringer's solution containing tisokinase (96 IU/mL) infused at 20 mL/hr for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated only with baseline treatment
Number of subjects: 60
Study: 17126565

Group type: EXPERIMENTAL
Intervention: Subliminal primes with a short prime-target ISI interval (100 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal primes with a long prime-target ISI interval (800 ms)
Number of subjects: 0
Study: 16155135

Group type: EXPERIMENTAL
Intervention: PGLA-coated coils
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bare platinum coils
Number of subjects: 51
Study: 12576372

Group type: EXPERIMENTAL
Intervention: Anticoagulation service (ACS) monitoring
Number of subjects: 231

Group type: COMPARATOR
Intervention: Primary care providers (PCPs) monitoring
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: ACS monitoring
Number of subjects: 231

Group type: COMPARATOR
Intervention: PCP monitoring
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Patients who maintained their warfarin dose
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Patients who decreased their dose by 1 to 20%
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Patients who decreased their dose by 21 to 43%
Number of subjects: 231
Study: 10536540

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 95% Spectral Edge Frequency (SEF)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Approximate Entropy (ApEn)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 37
Study: 8542169

Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide (single evening dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide (twice daily for 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1466208

Group type: EXPERIMENTAL
Intervention: Antithrombin concentrate (AT group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-antithrombin concentrate (non-AT group)
Number of subjects: 32
Study: 6233335

Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.1 mg/kg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.5 mg/kg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Isotretinoin 1.0 mg/kg/day
Number of subjects: 150
Study: 30944226

Group type: EXPERIMENTAL
Intervention: Hammock positioning (n = 13)
Number of subjects: 26
Study: 30567583

Group type: EXPERIMENTAL
Intervention: Zika virus testing using ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zika virus testing using PRNT
Number of subjects: 0
Study: 27164459

Group type: EXPERIMENTAL
Intervention: 94 mL of prewarmed iopromide 240 mg I/mL at 8.3 mL/s
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 75 mL of 300 mg I/mL at 6.7 mL/s
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 61 mL of 370 mg I/mL at 5.4 mL/s
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 200
Study: 24647852

Group type: EXPERIMENTAL
Intervention: Lateral release procedure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Outpatient clinic imaging
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Surgery (before and after lateral release)
Number of subjects: 33
Study: 22523335

Group type: COMPARATOR
Intervention: Bradykinin infusion in the left leg (Study I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemia (Study II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bradykinin during euglycemic hyperinsulinemia (Lean group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bradykinin during euglycemic hyperinsulinemia (Obese group)
Number of subjects: 20
Study: 19692213

Group type: EXPERIMENTAL
Intervention: High MUFA diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: High SFA diet
Number of subjects: 60
Study: 17660604

Group type: EXPERIMENTAL
Intervention: Depakin-chrono, 500 mg tablets, daily dose varied 250-1500 mg/day
Number of subjects: 20
Study: 16105981

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 1500
Study: 11967671

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral laparoscopic hernia repair (TAPP)
Number of subjects: 1336

Group type: COMPARATOR
Intervention: Unilateral laparoscopic hernia repair (TAPP)
Number of subjects: 1336
Study: 10808386

Group type: EXPERIMENTAL
Intervention: BAL from s.A (lung segment with most extensive involvement)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BAL from s.B (lung segment with least extensive involvement)
Number of subjects: 28

Group type: COMPARATOR
Intervention: BAL from s.A and s.B in RD group
Number of subjects: 28

Group type: COMPARATOR
Intervention: BAL from s.A and s.B in controls
Number of subjects: 28
Study: 7775675

Group type: EXPERIMENTAL
Intervention: Electronic toothbrush
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control toothbrush
Number of subjects: 80
Study: 2182578

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy (included in some trials)
Number of subjects: 0
Study: 7000250

Group type: EXPERIMENTAL
Intervention: Clindamycin injection before operation and antibiotic capsules after operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injection and antibiotic capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injection and placebo capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin injection before operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic injection
Number of subjects: 0
Study: 31126265

Group type: EXPERIMENTAL
Intervention: Smoking cessation programs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interest in reducing smoking
Number of subjects: 40
Study: 27997703

Group type: EXPERIMENTAL
Intervention: Influenza vaccine administered on day 1 of chemotherapy (n=43)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Influenza vaccine administered on day 11 of chemotherapy (n=54)
Number of subjects: 97
Study: 26176535

Group type: COMPARATOR
Intervention: Control arm of cluster randomised controlled trials
Number of subjects: 58601
Study: 22576325

Group type: EXPERIMENTAL
Intervention: FS - composite resin Filtek Supreme Plus (3M/ESPE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RMGIC + FS - resin-modified glass ionomer cement Vitrebond Plus (3M/ESPE) + FS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FFS + FS - flowable composite resin Filtek Supreme Plus Flowable (3M ESPE) + FS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no aging)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simulated Aging - Thermal/Mechanical cycling (3,000 cycles, 20‐80 °C/500,000 cycles, 50 N)
Number of subjects: 12
Study: 21729116

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride drops orally at a dose of 0.7 mg/kg
Number of subjects: 69
Study: 19247684

Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 18
Study: 16938719

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture and moxa (TCM group, n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham acupuncture (control group, CG, n = 14)
Number of subjects: 29
Study: 15292806

Group type: EXPERIMENTAL
Intervention: CT-based computer-assisted surgery system
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cusum technique for evaluation
Number of subjects: 78
Study: 11374408

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g b.i.d.
Number of subjects: 221

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1-2 mg/kg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 221
Study: 9243683

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine, 3 mg.kg‐1, diluted to 2 ml with saline, 1 ml per naris
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (intranasal saline, 2 ml, 1 ml per naris)
Number of subjects: 40
Study: 8467340

Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-Continuous Passive Motion (non-CPM)
Number of subjects: 30
Study: 2830047

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (1 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29699964

Group type: EXPERIMENTAL
Intervention: Single-session, Web-based parenting intervention
Number of subjects: 349

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 349
Study: 27031035

Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Strategy (SHS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal Sleep Hygiene Strategy (NSHS)
Number of subjects: 20
Study: 24925006

Group type: EXPERIMENTAL
Intervention: Vancomycin for inhalation (250 mg twice a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Taste-matched placebo
Number of subjects: 40
Study: 23388602

Group type: EXPERIMENTAL
Intervention: Cavinton in infusions and then in tablets (cavinton forte)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Standard treatment without cavinton
Number of subjects: 661
Study: 20921122

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation of the nucleus accumbens
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 17945482

Group type: EXPERIMENTAL
Intervention: SU11248 (sunitinib malate)
Number of subjects: 0
Study: 17450677

Group type: COMPARATOR
Intervention: IL-1 beta antagonist (single intraarticular injection of 50 or 150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1 beta antagonist (150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha therapy
Number of subjects: 0
Study: 12755009

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-II receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists
Number of subjects: 0
Study: 10871968

Group type: EXPERIMENTAL
Intervention: High baseline depressive symptoms
Number of subjects: 5201
Study: 8901169

Group type: EXPERIMENTAL
Intervention: contextually-based analogical reasoning problems
Number of subjects: 10

Group type: COMPARATOR
Intervention: standardised test analogy items
Number of subjects: 10
Study: 1293252

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 6331100

Group type: EXPERIMENTAL
Intervention: calendar prompt and home‐based attendance contract intervention (Experimental group, N = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: standard aftercare treatment arrangements (Control group, N = 25)
Number of subjects: 50
Study: 30957402

Group type: EXPERIMENTAL
Intervention: OptiBIRTH intervention (enhanced women-centred care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 0
Study: 30157824

Group type: EXPERIMENTAL
Intervention: Early sacral nerve stimulation (SNM) with Medtronic PrimeAdvanced Surescan 97,702 Neurostimulator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care for neurogenic bladder (NGB) including anticholinergic medications and usual bladder management strategies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Early sacral nerve stimulation (SNM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care for neurogenic bladder (NGB)
Number of subjects: 60
Study: 26756747

Group type: EXPERIMENTAL
Intervention: Dorzolamide/Timolol Fixed Combination (DTFC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 44
Study: 25175099

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (150 mg/day erlotinib + 15 mg/kg bevacizumab every 3 weeks)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Erlotinib alone (150 mg/day)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 154

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 21335480

Group type: EXPERIMENTAL
Intervention: Pharmacist care program (regular drug-counseling sessions with pharmacists)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pharmacist care program
Number of subjects: 105
Study: 19411049

Group type: EXPERIMENTAL
Intervention: Food Stamp Nutrition Education (FSNE)
Number of subjects: 219
Study: 17457004

Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein antrum isolation using a larger Lasso catheter (25-30 mm in diameter)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Segmental pulmonary vein isolation using a regular Lasso catheter (15-20 mm in diameter)
Number of subjects: 187
Study: 14667521

Group type: EXPERIMENTAL
Intervention: Ileal W neobladder with serous lined extramural tunnel (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hemi-Kock pouch with intussuscepted nipple valve (group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 11557704

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox) 50 U per axilla
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox)
Number of subjects: 307
Study: 9564798

Group type: EXPERIMENTAL
Intervention: High starting dose of 1 mg budesonide twice daily followed by a stepwise decrease of 25% every second day for 1 week (group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low dose of 0.25 mg budesonide twice daily for 1 week (group B)
Number of subjects: 42
Study: 8171370

Group type: EXPERIMENTAL
Intervention: Low pressure polymethylmethacrylate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milled bone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matchstick bone
Number of subjects: 0
Study: 2741904

Group type: EXPERIMENTAL
Intervention: Personal interview
Number of subjects: 216

Group type: COMPARATOR
Intervention: Mailed self‐administered questionnaire
Number of subjects: 216
Study: 31960447

Group type: EXPERIMENTAL
Intervention: Topical treatment containing 5% pyridine-2, 4-dicarboxylic acid diethyl ester and 0.25% resveratrol
Number of subjects: 79
Study: 31533972

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Changes in polysomnographic severity
Number of subjects: 398

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 398
Study: 27328649

Group type: EXPERIMENTAL
Intervention: High Cadence Training (HCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low Cadence Training (LCT)
Number of subjects: 0
Study: 25970339

Group type: EXPERIMENTAL
Intervention: Group 2 (BIS monitoring)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 1 (Control - standard practice)
Number of subjects: 40
Study: 23052571

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Trazodone 25 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Behavioral performance
Number of subjects: 19
Study: 21447078

Group type: EXPERIMENTAL
Intervention: Preoperative paravertebral block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postoperative paravertebral block
Number of subjects: 60
Study: 19811459

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Visual assessment of bilirubin (VaB)
Number of subjects: 617
Study: 16690128

Group type: EXPERIMENTAL
Intervention: 0.59-mg fluocinolone acetonide implant
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 2.1-mg fluocinolone acetonide implant
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control (fellow non-implanted eyes)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 0.59-mg and 2.1-mg fluocinolone acetonide implants
Number of subjects: 278
Study: 16287954

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/d; n = 4439)
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Usual-dose simvastatin (20 mg/d; n = 4449)
Number of subjects: 8888

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/d)
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Usual-dose simvastatin (20 mg/d)
Number of subjects: 8888
Study: 12221217

Group type: EXPERIMENTAL
Intervention: Soy protein (SP) 40 g daily for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk-based protein (MP) 40 g daily for 3 months
Number of subjects: 0
Study: 10211152

Group type: EXPERIMENTAL
Intervention: Routine care plus the social work intervention (n = 85)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Routine care (n = 77)
Number of subjects: 162
Study: 7605178

Group type: EXPERIMENTAL
Intervention: Concentric and eccentric contractions in patients with CLBP
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sitting posture with feet against the floor
Number of subjects: 48